Media

Corgentech Appoints Patrick Broderick as General Counsel and Corporate Secretary

SOUTH SAN FRANCISCO, Calif., Jul 13, 2004 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, announced today that Patrick Broderick has joined the Company as vice president, general counsel and corporate secretary. He will be responsible for overseeing all aspects of the Company's legal affairs.

Prior to joining Corgentech, Mr. Broderick was vice president, secretary and general counsel of DaVita Inc., the largest independent provider of dialysis services in the United States, where he was responsible for all legal affairs of the company. From 1999 to 2002, he served as general counsel of COR Therapeutics, Inc. where he managed all of COR's legal matters, including its intellectual property portfolio and securities offerings. He also oversaw the company's merger with Millennium Pharmaceuticals.

"Patrick is a seasoned industry veteran who brings over a decade of directly relevant experience handling the legal affairs at leading biotech and healthcare companies to Corgentech's management team," said John P. McLaughlin, Corgentech's president and chief executive officer. "His insight into today's complex legal environment will be invaluable as we move toward commercial development of our lead product candidate and continue to build our pipeline of novel transcription factor decoys."

From 1993 to 1998, Mr. Broderick served in a variety of in-house legal positions for McKesson Corporation, including as counsel to McKesson Bioservices Corporation and Healthcare Delivery Systems, Inc. Prior to joining McKesson, he served as an attorney at the law firms of Morrison & Foerster and McCutchen, Doyle, Brown and Enersen. He received his JD from Yale Law School and BA from Harvard College.

About Corgentech

Corgentech is a biopharmaceutical company engaged in the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF decoys. We are creating a pipeline of novel therapeutics based on our proprietary TF decoy technology, focused initially on the treatment of cardiovascular disease, inflammatory disease, such as arthritis and dermatitis, and cancer. For more information on the company and its technology, visit www.corgentech.com.

Forward-Looking Statements

This press release contains forward-looking statements, including without limitation all statements related to our clinical trials, product candidates and collaboration with Bristol-Myers Squibb. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "slated," "goal" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of our clinical trials, intellectual property matters, difficulties or delays in obtaining regulatory approval, manufacturing our lead product candidate, competition from other pharmaceutical or biotechnology companies, our ability to obtain additional financing to support our operations and other risks detailed in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2003 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2004. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Corgentech undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

SOURCE Corgentech Inc.

Richard Powers of Corgentech Inc., +1-650-624-9600, or
[email protected]; or Daryl Messinger of WeissCom Partners,
+1-415-999-2361, or [email protected], for Corgentech Inc.

http://www.corgentech.com

News Provided by COMTEX